International Biotechnology Trust’s NovoCure NVCR Stock Holding History

International Biotechnology Trust’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$1.19M	Buy	74,000 +42,000	+131%	+$1.21M	0.4%	47
2023 Q2	$1.33M	Hold	32,000	–	–	0.4%	42
2023 Q1	$1.92M	Hold	32,000	–	–	0.54%	41
2022 Q4	$2.34M	Hold	32,000	–	–	0.72%	33
2022 Q3	$2.43M	Buy	32,000 +29,776	+1,339%	+$2.32M	0.78%	37
2022 Q2	$32K	Buy	+2,224	New	+$168K	0.33%	54
2020 Q1	–	Sell	-35,500	Closed	-$2.99M	–	61
2019 Q4	$2.99M	Buy	+35,500	New	+$2.87M	1.08%	26

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return

International Biotechnology Trust's NVCR Position: Q3 2023 in Review

International Biotechnology Trust increased its NovoCure (NVCR) stake by 131% in Q3 2023, buying an estimated $1.21M and bringing the position to 74,000 shares worth $1.19M. The position accounts for 0.4% of the portfolio, ranked #47.

International Biotechnology Trust first reported a position in NVCR in Q4 2019 and has held it in 7 quarters since. The position peaked at $2.99M in Q4 2019. 227 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

International Biotechnology Trust held 74,000 shares of NovoCure worth $1.19M as of Q3 2023.
International Biotechnology Trust bought 42,000 NovoCure shares in Q3 2023, an estimated $1.21M.
NovoCure made up 0.4% of International Biotechnology Trust's portfolio in Q3 2023, its #47 holding.
International Biotechnology Trust first reported a position in NovoCure in Q4 2019 and has held it in 7 quarters since.
International Biotechnology Trust's NovoCure position peaked at $2.99M in Q4 2019.
227 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.